Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate, inclusive and female-friendly
Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate, inclusive and female-friendly
批准号:
10070730
负责人:
金额:
$34.18万
依托单位:
依托单位国家:
英国
项目类别:
EU-Funded
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Breast cancer (BC) is the most common cancer in women worldwide, affecting 1 in 8 women. The figures from WHO’s International Agency for Research on Cancer estimate that in 2020 worldwide cases of breast cancer accounted for 24% of all cancers in women (2.26 million women and 685,000 deaths globally). Mammography is the gold standard technology for breast screening, which has been demonstrated through different randomized controlled trials to reduce breast cancer mortality. However, it has limitations and potential harms, such as the use of ionizing radiation, breast compression and performance restrictions due to the intrinsic nature of X-rays. In particular, breast density is a restrictive property that can prevent breast cancer detection in mammograms of women with radiographically dense breasts. Other existing techniques (MRI, Ultrasound, biopsy) also suffer from drawbacks. The overall aim of the MammoScreen proposal is to generate evidence about the use of MammoWave (a technology developed by UBT) as screening technique in population-based programs promoted by National or Regional Health Systems, to reach a revolution in breast screening. To do so, the consortium aimsto confirm that MammoWave reachessensitivity>90% and specificity>95% in BC detection on 10000 study participants undergoing regular screening programs. MammoWave uses safe non-invasive and non-ionizing microwave signals, does not apply any compression to the breast and is very effective with dense breasts. Hence it can extend the breast screening to younger women aged 20-49 (98 million women in Europe). This group accounts for ~30% of breast cancers in 2020. A comprehensive health economic assessment will be undertaken in this project and innovative way to implement patient engagement approaches is sought. An effective policy makers’ engagement plan will be carried out to ensure that MammoWave is recommended as screening approach due to the benefits that it brings to women and healthcare systems. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于深穿透拉曼光谱的安全光照剂量的深层病灶无创检测与深度预测
-
批准号:82372016
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:林俐
-
依托单位:
叶绿体蛋白SAFE1和SAFE2介导单线态氧信号转导的机理研究
-
批准号:32170284
-
项目类别:面上项目
-
资助金额:60万元
-
批准年份:2021
-
负责人:王良省
-
依托单位:
基于Safe screening的多任务稀疏学习理论与算法的研究
-
批准号:12071475
-
项目类别:面上项目
-
资助金额:51.0万元
-
批准年份:2020
-
负责人:徐义田
-
依托单位:
醛糖还原酶(AR)激活SAFE(JAKs/STATs)通路在抵抗下颌下腺缺血再灌注损伤中的作用
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:张思恩
-
依托单位:
基于Safe screening 的支持向量机的稀疏理论及其快速求解方法
-
批准号:11671010
-
项目类别:面上项目
-
资助金额:48.0万元
-
批准年份:2016
-
负责人:徐义田
-
依托单位:
Notch1与RISK/SAFE/HIF-1α信号通路整合在I-postC保护中的作用及其机制
-
批准号:81260024
-
项目类别:地区科学基金项目
-
资助金额:50.0万元
-
批准年份:2012
-
负责人:刘季春
-
依托单位:
氙气延迟后处理对兔脊髓缺血再灌注损伤的保护作用及SAFE细胞信号机制研究
-
批准号:81271387
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2012
-
负责人:程卫平
-
依托单位: